Alkis Papachristos, PharmD, PhD retweeted
📢 @ACSCAN #Pharmacogenomics summit is happening tomorrow!
Join Peter O’Donnell, MD from @UChicagoMed, to learn about University of Chicago’s experiences with prospective PGx testing in it's cancer patient populations. @UCCancerCenter @UChicagoHemOnc
ow.ly/87mA50OZIMP
#ASCO23 day 2 kicks off! Looking forward to the Developmental Therapeutics poster session - Immunotherapy & Molecularly Targeted agents #Immunotherapy #Immunooncoloy #TargetedTreatments🧬@ASCO #CancerResearch
2
135
Alkis Papachristos, PharmD, PhD retweeted
Pls RT! Let’s help @bekkiburgoyne to reach her goal @Anish_m_tailor @PinkieChambers @meerad30 @ClareGeoghegan @SebMasento @Jharchowal @PaddaAmandeep @DrDereckG @panisphik @BOPACommittee
Alkis Papachristos, PharmD, PhD retweeted
Replying to @HsiehLab @FaltasLab
@FaltasLab is brilliant & very famous all over the world including Greek newspapers, proof here:
ethnos.gr/health/article/240…
@minaseconomides @DRBakaloudiMD @alkis_p @EfstathiouEleni @PavlosMsaouel @g_mountzios @MichalisLiontos @AKyriazoglou @mkmoutafi Bishoy will visit Greece soon! – at Seattle, WA
I am glad to share our newest publication presenting a novel ML approach to identify predictive biomarkers in patients receiving Bevacizumab-based regimes for mCRC ascpt.onlinelibrary.wiley.co… #MachineLearning #colorectalcancer #PrecisionMedicine @EleniKaratz
1
Alkis Papachristos, PharmD, PhD retweeted
DPYD genetic testing and the future of pharmacogenomic testing in routine care
#PJgenomics @JessicaKPharma1 @EmmaGrovesPharm @oncology_pharm @GeneticBill
pharmaceutical-journal.com/a…
Alkis Papachristos, PharmD, PhD retweeted
A new mechanism involved in the anti-cancer immune response has been identified and may have implications for targeting antigens. ms.spr.ly/6010bZRxk
Last day of #ASCO2022 @ASCO it was great to be back in #Chicago, learn the latest advances in #oncology #immunoOncology and meeting many friends and colleagues. See you next year!
3
Alkis Papachristos, PharmD, PhD retweeted
Starting at 3 PM: Dr. Peter O'Donnell will moderate a panel discussion on the state of pharmacogenetic testing to personalize cancer therapy. meetings.asco.org/2022-asco-… #ASCO22
Day 3 @ASCO #ASCO2022 starts 🔜 Looking forward to the Developmental Therapeutics-Immunotherapy poster session #Immunotherapy #immunoOncology #biomarker – at Chicago, IL
1
Alkis Papachristos, PharmD, PhD retweeted
Today's the day - a superb lineup of speakers and panelists on #Gettingthedoseright. Along with Dr. Mirat Shah @FDAOncology, we'll be kicking off Day 1 in 2 short hours with @realrickpazdur and @lillian_siu. Ready to talk #oncopharm #clinicaltrials and all things dose-related
Getting the Dose Right: Optimizing Dose Selection Strategies in Oncology – An FDA-ASCO Virtual Workshop - 05/03/2022 fda.gov/news-events/fda-meet…
Alkis Papachristos, PharmD, PhD retweeted
New article: Lurbinectedin-induced thrombocytopenia: the role of body surface area link.paperbirds.me/SMnv67 #lungcancer #oncology
Lurbinectedin-induced thrombocytopenia: the role of body surface area pubmed.ncbi.nlm.nih.gov/3536…
Our article on factors associated with BSA and thrombopoiesis, which may affect the exposure-toxicity relationship of cytotoxics #LCSM #chemo
2
Alkis Papachristos, PharmD, PhD retweeted
Our lab at @NIAIDNews @NIH is hiring a Staff Scientist to work in bench-to-bedside research projects in the areas of fungal immunology, inflammation and autoimmunity. Reach out if you are interested and please retweet!
niaid.nih.gov/about/staff-sc…
This is fascinating!!! Decade-long leukaemia remissions with persistence of CD4+ CAR T cells | Nature nature.com/articles/s41586-0…
Alkis Papachristos, PharmD, PhD retweeted
Updated @cpicpgx guideline is available for CYP2C19-clopidogrel. Nice to see this timely update after several recent RCTs.
ascpt.onlinelibrary.wiley.co…
Alkis Papachristos, PharmD, PhD retweeted
Nice review on the influence of inflammation on CYP450 activity. TAKE HOME: Inflammation down-regulates CYP3A, CYP1A2, & CYP2C19 activity but has no/minimal impact on CYP2D6 activity. Important to consider when interpreting & implementing PGx testing. frontiersin.org/article/10.3…
Alkis Papachristos, PharmD, PhD retweeted
Replying to @PavlosMsaouel
@PavlosMsaouel @minaseconomides @ThalesPapaG @alkis_p @MarilenaMelas @kdrosato @Chris_Lisgaras @EAntonarakis @ValsamoA @mtsiatas @g_mountzios @EllokGr @DMakrakisMD @LDiamantMD @FaltasLab @EfrosiniTsouko @siadaneshmand @UroDocAsh @SWilliams_MD @DrJohnSfakianos “spirit of freedom” – at Seattle, WA





















